**12. References**


<sup>\*</sup> Corresponding Author

stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003; 88:4186–92.

1199

12:1073–1079

Reprod. Updat., 2000,6: 139–148

Biochem Mol Biol. 2005 ; 97:416-20.

cycles. Fertil Steril 2001; 76:1144–1149

transfer cycles. Fertil Steril. 2001 Aug;76(2):394-6

menopur and bravelle. Fertil Steril 2007; 87(S2):S24

Luteal Phase Support in ART: An Update 169

[29] van Broekhoven F., Backstrom T., Verkes R.J. Oral progesterone decreases saccadic eye velocity and increases sedation in women Psychoneuroendocrinology, 2006;31 : 1190–

[30] Bulletti, D. de Ziegler, C. Flamigni, E. Giacomucci, V. Polli, G. Bolelli et al. Targeted drug delivery in gynaecology: the first uterine pass effect Hum. Reprod., 1997;

[31] Cicinelli E., De Ziegler D., Bulletti C., M.G. Matteo, Schonauer L.M., Galantino P. Direct transport of progesterone from vagina to uterus Obstet. Gynecol., 2000; 95: 403–406 [32] Tavaniotou A., Smitz J., Bourgain C., Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments Hum.

[33] Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study.J Steroid

[34] Patki A, Pawar VC. Modulating fertility outcome in assisted reproductive technologies

[35] Friedler S, Raziel A, Schachter M, Strassburger D, Bukovsky I, Ron-El R. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between

[36] Bacq Y, Sapey T.,. Bréchot M.C, Pierre F.,. Fignon A and. Dubois F, Intrahepatic cholestasis of pregnancy: a French prospective study, Hepatology 26 (1997), pp. 358–364 [37] Licciardi FL, Kwiatkowski A, Noyes NL, et al. Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertil Steril 1999; 71:614–618 [38] Abate A, Perino M, Abate FG, et al. Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A

[39] Propst AM, Hill JA, Ginsburg ES, et al. A randomized study comparing crinone 8% and intramuscular progesterone supplementation in in vitro fertilization-embryo transfer

[40] Costabile L, Gerli S, Manna C, Rossetti D, Di Renzo GC, Unfer V. A prospective randomized study comparing intramuscular progesterone and 17alphahydroxyprogesterone caproate in patients undergoing in vitro fertilization-embryo

[41] Unfer V, Casini ML, Costabile L, Gerli S, Baldini D, Di Renzo GC. 17 alphahydroxyprogesterone caproate versus intravaginal progesterone in IVF-embryo transfer

cycles: a prospective randomized study. Reprod Biomed Online. 2004;9(1):17-21. [42] Doody K, Shamma FN, Paulson RJ, et al. Endometrin for luteal phase support in a randomized, controlled, open label, prospective IVF clinical trial using a combination of

comparative randomized study. Clin Exp Obstet Gynecol 1999; 26:203–206

by the use of dydrogesterone. Gynecol Endocrinol. 2007 Suppl 1:68-72.

vaginal and oral administration. Hum Reprod. 1999 ;14:1944-8.


[29] van Broekhoven F., Backstrom T., Verkes R.J. Oral progesterone decreases saccadic eye velocity and increases sedation in women Psychoneuroendocrinology, 2006;31 : 1190– 1199

168 Enhancing Success of Assisted Reproduction

13:3315–18.

12:27–32

746–750.

Steril 2000;73:516–21

Supplement 1, Pages S29-S34

Steril., 1985;44 : 622–626

Reviews 2009;61: 871–882

2009 , : 19, S 4, 1–13

stimulation with recombinant follicle-stimulating hormone and GnRH antagonist

[13] Penarrubia J, Balasch J, Fabregues F, et al. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin releasing hormone agonist-induced ovulation in gonadotrophin stimulated cycles. Hum Reprod 1998;

[14] Albano C, Grimbizis G, Smitz J, et al. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin

[15] Fatemi HM The luteal phase after 3 decades of IVF Reproductive BioMedicine Online,

[16] Friedler S, Gilboa S, Schachter M, et al. Luteal phase characteristics following GnRH antagonist or agonist treatment – a comparative study. Reprod Biomed Online 2006;

[17] Soliman S, Daya S, Collins J, Hughes EG The role of luteal support in infertility treatments: a meta-analysis of randomized trials. Fertil Steril 1994 ; 61:1068–76 [18] Pritts E, Atwood A Luteal phase support in infertility treat- ment: a meta-analysis of the

[19] Daya S, Gunby J Luteal phase support in assisted reproduc-tion cycles. Cochrane

[20] Nosarka S, Kruger T, Siebert I, et al. Luteal phase support in in vitro fertilization:

[21] van der Linden M, Buckingham K, Farquhar C, Kremer JAM, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews

[22] Ottoson UB, Johansson BG, Von Schoultz B Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. American Journal of Obstetrics and Gynecology 1985;151:

[24] Levine H, Watson N. Comparison of the pharmacokinetics of Crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertil

[25] Daya S Luteal support: Progestogens for pregnancy protection Maturitas 2009, 65:

[26] R. Dmitrovic, V. Vlaisavljevic, D. Ivankovic Endometrial growth in early pregnancy

[27] Maxson W.S, Hargrove J.T. Bioavailability of oral micronized progesterone Fertil.

[28] Margit M. Janát-Amsbury,Kavita M. Gupta, Caroline D. Kablitz, Drug delivery for in vitrofertilization: Rationale, current strategies and challenges Advanced Drug Delivery

metaanalysis of randomized trials. Gynecol Obstet Invest 2005; 60:67–74.

releasing hormone antagonist Cetrorelix. Fertil Steril 1998: 70:357–9.

cotreatment. J Clin Endocrinol Metab 2003; 88:4186–92.

randomized trials. Hum Reprod1 2002; 7:2287–99

Database Syst Rev, 2004; CD004830.

2011, Issue 10. Art. No.: CD009154. DOI:

[23] Penzias AS. Luteal phase support. Fertil Steril 2002; 77:318–323

after IVF/ET J. Assist. Reprod. Genet. 2008; 25:453-9.


[43] Yanushpoisky E, Hurwitz S, Greenberg L, et al. Comparison of crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertil Steril 2008; 89:458–467.

Luteal Phase Support in ART: An Update 171

[56] Hughes JN, Cedrin-Durnerin I, Bstandig B, et al. Administration of gonadotropinreleasing hormone agonist during the luteal phase of the GnRH-antagonist IVF cycles.

[57] Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzi TB, Devroey P, Tarlatzis BC. Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: a

[58] Mochtar MH, Hogerzeil HV, Mol BW Progesterone alone versus progesterone combined with HCG as luteal support in GnRHa/HMG induced IVF cycles: a

[59] Fujimoto A, Osuga Y, Fujiwara T, et al. Human chorionic gonadotrophin combined with progesterone for luteal support improves pregnancy rate in patients with low late-

[61] Smitz J, Devroey P, Braeckmans P, Camus M, Khan L, Staessen C, et al. Management of failed cycles in an IVF/GIFT programme with the combination of a GnRH analogue and

[62] Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P,Devroey P. An update of luteal phase support in stimulated IVF cycles.Hum Reprod Update 2007;13:581. [63] Ghanem M E., Ehab E. Sadek, Elboghdady L. A.. Helal A S, Gamal Anas, Eldiasty A Bakre N I., Houssen M .The effect of luteal phase support protocol on cycle outcome and luteal phase hormone profile in long agonist protocol intracytoplasmic sperm injection cycles: a randomized clinical trial , Fertility and Sterility 2009 92: 486-493 [64] Var T, Tonguc EA, Doğanay M, Gulerman C, Gungor T, Mollamahmutoglu L. A comparison of the effects of three different luteal phase support protocols on in vitro

fertilization outcomes: a randomized clinical trial. Fertil Steril. 2011 95:985-9.

review and meta-analysis. Fertil Steril 2008;90: 2116-25.

randomized prospective study. Fertil Steril 2001; 76:1140–3.

[65] Gelbaya TA, KyrgiouM, Tsoumpou I, Nardo LG. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperminjec- tion cycles: a systematic

[66] Jee BC, Suh CS, Kim SH, Kim YB, Moon SY. Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis Fertil Steril. 2010 93:428-

[67] Williams SG, Oehninger S, Gibbons WE, et al. Delaying the initiation of progesterone supplementation results in decreased pregnancy rates after in vitro fertilization: a

[68] Mochtar MH, Van Wely M, Van der Veen F. Timing luteal phase support in GnRH agonist down-regulated IVF/embryo transfer cycles. Hum Reprod 2006; 21:905–908 [69] Schmidt KL, Ziebe S, Popovic B, et al. Progesterone supplementation during early gestation after in vitro fertilization has no effect on the delivery rate. Fertil Steril 2001;

systematic review and meta-analysis. Hum Reprod Update. 2011 ;17:734-40.

midluteal es-tradiol levels in IVF cycles. J Assist Reprod Genet 2002 19:550–4. [60] Ludwig M, Finas A, Katalinic A, et al. (2001) Prospective, random-ized study to evaluate the success rates using hCG, vaginal pro-gesterone or a combination of both

Hum Reprod 2006; 21 (Suppl. 1):O-007.

hMG. Hum Reprod 1987;2:309–14.

36

75:337–341

randomized clinical trial.Hum Reprod 1996; 11:1602–5

for luteal phase support. Acta Obstet Gynecol Scand 80:574–82


[56] Hughes JN, Cedrin-Durnerin I, Bstandig B, et al. Administration of gonadotropinreleasing hormone agonist during the luteal phase of the GnRH-antagonist IVF cycles. Hum Reprod 2006; 21 (Suppl. 1):O-007.

170 Enhancing Success of Assisted Reproduction

Fertil Steril 2008; 89:458–467.

313-315 ,2002

Hum. Reprod., 1999, 14: 606–610

and Reproductive Biology 2007; 131: 182–188

assisted reproduction. Fertil Steril 2005;83:1641–9.

large prospective trial. Fertil Steril. 2012;97:344-8.

Fertil Steril. 2010 94:2083-7.

19:1176–80

[43] Yanushpoisky E, Hurwitz S, Greenberg L, et al. Comparison of crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial.

[44] Levy T., Gurevitch S., Bar-Hava I., Ashkenazi J., Magazanik A.,. Homburg R et al. Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet

[45] Germond M, Capelli P., Bruno G, Vesnaver S, Senn A., Rouge N ,. Biollaz J, Comparison of the efcacy and safety of two formulations of micronized progesterone (Ellios™and Utrogestan™) used as luteal phase support after in vitro fertilization Fertil Steril 77:

[46] Yu Ng EH , Chan CCW, Tang OS, Ho PC A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment European Journal of Obstetrics & Gynecology

[47] Ludwig M, Schwartz P, Babahan B, Katalinic A, Weiss JM, Felberbaum R, Al-Hasani S, Diedrich K. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. Eur J Obstet Gynecol Reprod Biol. 2002 103:48-52. [48] Kleinstein J. Efcacy and tolerability of vaginal progesterone capsules (Utrogest™ 200) compared with progesterone gel (Crinone™ 8%) for luteal phase support during

[49] Silverberg KM, Vaughn TC, Hansard LJ, Burger NZ, Minter T.Vaginal (Crinone 8%) gel vs. intramuscular progesterone in oil for luteal phase support in in vitro fertilization: a

[50] Polyzos NP, Messini CI, Papanikolaou EG, Mauri D, Tzioras S, Badawy A, Messinis IE. Vaginal progesterone gel for luteal phase support in IVF/ICSI cycles: a meta-analysis.

[51] Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod 2006; 21:1894–1900 [52] Tesarik J, Hazout A, Mendoza-Tesarik R, et al. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and

antagonist-treated ovarian stimulation cycles. Hum Reprod 2006; 21:2572–2579 [53] Ata B, Yakin K, Balaban B, et al. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized,

[54] Tesarik J, Hazout A, Mendoza C Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod 2004

[55] Pirard C, Donnez J, Loumaye E GnRH agonist as novel luteal support: results of a randomised, parallel group, feasibility study using intranasal administration of

controlled double blind study. Hum Reprod 2008; 23:668–673

buserelin. Hum Reprod 2005 20:1798–804.



[70] Aboulghar MA, Amin Y, Al-Inany H, et al. Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an

[71] Andersen AN, Popovic-Todorovic B, Schmidt KT, et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a

additional three weeks. Hum Reprod 2008; 33:857–862

randomized controlled trial. Hum Reprod 2002; 17:357–361
